Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
150.33
-2.01 (-1.32%)
At close: Sep 4, 2026, 4:00 PM EDT
152.00
+1.67 (1.11%)
After-hours: Sep 4, 2026, 7:58 PM EDT
Merck & Co. Market Cap
Merck & Co. has a market cap or net worth of $370.89 billion as of September 4, 2026. Its market cap has increased by 76.39% in one year.
Market Cap
370.89B
Enterprise Value
417.66B
1-Year Change
76.39%
Ranking
Category
Stock Price
$150.33
ChartMarket Cap Chart
Since December 1, 1998, Merck & Co.'s market cap has increased from $187.00B to $370.89B, an increase of 98.34%. That is a compound annual growth rate of 2.50%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 4, 2026 | 370.89B | 41.96% |
| Dec 31, 2025 | 261.26B | 3.82% |
| Dec 31, 2024 | 251.65B | -8.91% |
| Dec 29, 2023 | 276.26B | -1.79% |
| Dec 30, 2022 | 281.30B | 45.31% |
| Dec 31, 2021 | 193.59B | -6.46% |
| Dec 31, 2020 | 206.96B | -10.62% |
| Dec 31, 2019 | 231.56B | 16.54% |
| Dec 31, 2018 | 198.69B | 29.61% |
| Dec 29, 2017 | 153.30B | -5.55% |
| Dec 30, 2016 | 162.31B | 10.00% |
| Dec 31, 2015 | 147.55B | -8.86% |
| Dec 31, 2014 | 161.90B | 10.71% |
| Dec 31, 2013 | 146.24B | 17.50% |
| Dec 31, 2012 | 124.46B | 8.31% |
| Dec 30, 2011 | 114.91B | 3.49% |
| Dec 31, 2010 | 111.03B | 44.07% |
| Dec 31, 2009 | 77.07B | 19.91% |
| Dec 31, 2008 | 64.27B | -49.18% |
| Dec 31, 2007 | 126.48B | 33.62% |
| Dec 29, 2006 | 94.66B | 36.08% |
| Dec 30, 2005 | 69.56B | -2.41% |
| Dec 31, 2004 | 71.27B | -30.66% |
| Dec 31, 2003 | 102.79B | -19.14% |
| Dec 31, 2002 | 127.12B | -4.96% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 1.02T |
| Johnson & Johnson | 663.28B |
| AbbVie | 453.19B |
| Novartis AG | 304.21B |
| AstraZeneca | 251.79B |
| Amgen | 236.38B |
| Novo Nordisk | 205.51B |
| Gilead Sciences | 187.23B |